Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319034 | 0.82 | GSK3B (0.53) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL2027674 | 0.80 | MAPT (0.47) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL12272526 | 0.79 | KDM4E (0.43) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL318755 | 0.79 | HSD17B10 (0.42) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL7670938 | 0.78 | TSHR (0.45) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL3780362 | 0.78 | GPR35 (0.48) | HSD17B10MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL12555515 | 0.78 | GSK3B (0.38) | MAPTKMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL11888070 | 0.77 | MAPT (0.44) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL6593225 | 0.77 | MAPT (0.44) | HSD17B10TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL166726 | 0.77 | MAPT (0.54) | HSD17B10TSHRMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-119371425-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-116023359-B | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| CN-116023359-A | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20220289727-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-8404859-B2 | Thiazole and thiophene compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404859-B2 | Thiazole and thiophene compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404859-B2 | Thiazole and thiophene compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | GILLESPIE PAUL (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123471-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | GILLESPIE PAUL (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123471-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | GILLESPIE PAUL (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289727-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | HSD17B10 226/4885TSHR 2164/4885MAPT 3136/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | HSD17B10 1427/4885TSHR 2786/4885MAPT 4871/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | HSD17B10 1197/4885TSHR 497/4885MAPT 4872/4885 |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | TSLP, CFTR, TPMT | HSD17B10 845/4885TSHR 441/4885MAPT 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.